2/2 By our read of the company’s filings, SLNO insiders should not have been permitted to immediately lock in the drug approval-related gains and to do so required a concession from the Compliance Officer, who happens to be the CFO. The Company’s Insider Trading Policy states.

1/2 $SLNO Soleno Therapeutics - Mgmt stock sales exhibit serious red flags. The speed and magnitude of stock dumping within days of FDA approval strikes us as rare and unusual, like many things w this company. Insiders appear a lot less bullish about their drug’s prospects than.

Join millions who have switched to Grok.

$SLNO Soleno Therapeutics - Citizen Petition submitted to FDA asking the agency to request Soleno to undertake a voluntary recall of VYKAT XR. We’ll update once FDA confirms receipt.

$SLNO Soleno Therapeutics - Mgmt now appears to be copping to *7 hospitalizations* per Guggenheim “flash note” yesterday. If the hospitalizations were for fluid retention and potential respiratory/heart failure, it’s hard for us to see how VYKAT XR has a viable path to staying on.

We are short $SLNO Soleno Therapeutics. Report now live at We intend to shortly file a Citizen Petition with the FDA, as well.

Today 9AM - the largest outright biotech scam in the US by market cap, based upon a 4-month investigation with >30 research interviews and extensive pharmacology, scientific, and statistical work. The scenario reminds us of recent events at Sarepta $SRPT.

$TMDX @SecKennedy and HRSA targeting the abuses that drive the organ transplant space, after recent NY Times investigative coverage. He still seems unaware that there is a publicly-traded for-profit company in the space with pressure to hit quarterly targets - what could possibly.

$TMDX To make the link more clear between Transmedics volume declines and the unfolding, recent crackdown on out-of-sequence organ offers, we explain how the liver match list works. The vast majority of livers are accepted within a couple of hundred miles from the donor, so they.

Zohran Mamdani: He votes for activists, not you

$TMDX A key driver of declining TransMedics volumes in Q3, we believe, is a recent crackdown on out-of-sequence organ placements in the aftermath of the NY Times article on Feb 26. The abuse is an underappreciated driver of TMDX's "Doordash-for-livers" business model - on a.

$TMDX Another chart to make it clear, based on our estimates and analysis.

$TMDX Third month in a row of declining flight volumes, according to our estimates derived from a third-party database. Obviously looks like share loss not seasonality. The downward trend is visibly sharper, longer, and started several months earlier (in the spring) than the

2/2 The underbelly of the DCD boom is the use of organs from low-quality donors - drug overdoses or alcoholics with fatty livers, geriatric livers from people >70 years old, and so forth. We think the majority of DCD liver recipients would reject the organ if they knew who it.

1/2 $TMDX We suggest 3 actions @SecKennedy could undertake immediately, which - almost overnight - would protect both organ donors and recipients, and wipe out most of the abuses in DCD organ procurement, as highlighted in the devastating NY Times articles. We elaborate on each.

$TMDX @RobertKennedyJr RFK already announcing reforms, which we think would put TransMedics business model at risk; plus a separate Congressional hearing tomorrow. Washington DC has still not figured out that a publicly-traded for-profit company is the grease that lubricates the.

2/2 We wonder if the TMDX surgeon was even licensed to practice medicine in the US. It’s troubling that they would proceed without bothering to use a $10 stethoscope or check for a pulse. We presume even a medical student could feel beating or breathing while palpating during.

1/2 $TMDX The NY Times published a bombshell article yesterday on attempts to remove organs from patients who exhibit clear signs of life - practices similar to poor foreign countries. The article mentions TransMedics. It was the lead story in the paper, following a similar NYT.

$TMDX Market share erosion should accelerate rapidly now that the OrganOx device appears cleared to fly as of June 2 per FDA labeling change. ChatGPT summary attached and here’s the link to the PMA supplement. We note several other competing devices are on the cusp of FDA

$TMDX New entrants continue to take share. Pennsylvania OPO (organ procurement organization) talking up their new OrganOx device. One of 57 OPO’s in the US. The emerging model seems to be that OPO’s pump organs without charge to local transplant centers so that they don’t have to

5/Note: Please refer to the disclosures in our Jan 10, 2025 report on TransMedics, which this post incorporates fully by reference and may be downloaded at  We remain short TransMedics.

Always curious and full of energy, Beagles turn every walk into an adventure 🐾🎉.

4/And the remainder that we see from the last year.